Rosuvastatin has Slight Edge Over Atorvastatin in reduction of all cause mortality among patients with dislipedemia, suggests study

• At six years' threshold, 2.57 per 100 person-years and 0.66 per 100 person-years seemed to contrast with 2.83 per 100 person-years and 0.90 per 100 person-years based on the studies of the CRDS database and the UKB database, respectively.

• These corresponded to CI reductions of -1.03% (95% CI, -1.44% to -0.46%) for the CRDS dataset and -1.38% (95% CI, -2.50% to -0.21%) in the UKB dataset.

• The rosuvastatin group also had lower rates of major adverse cardiovascular events and adverse liver outcomes in both the databases, hence a slight edge in protecting heart and liver conditions.

• Patients on rosuvastatin were at a higher risk of type 2 diabetes mellitus compared to that of patients on atorvastatin, with the patients at risk, it would be a problem.

The findings appear to indicate that although rosuvastatin has an edge over atorvastatin regarding a slight mortality benefit, the absolute differences were mostly small. This study contributes to the continuing evaluation of statin alternatives, providing health care professionals with information on slight differences between rosuvastatin and atorvastatin. For patients with a specific risk profile, like heightened susceptibility to diabetes, these results may be able to guide decisions on individualized therapy.

Reference:

Zhou, S., Chen, R., Liu, J., Guo, Z., Su, L., Li, Y., Zhang, X., Luo, F., Gao, Q., Lin, Y., Pang, M., Cao, L., Xu, X., & Nie, S. (2024). Comparative effectiveness and safety of atorvastatin versus rosuvastatin: A multi-database cohort study. Annals of Internal Medicine. https://doi.org/10.7326/m24-0178